Adverum Biotechnologies Inc. (NASDAQ:ADVM) has a beta value of 1.15 and has seen 1.34 million shares traded in the last trading session. The company, currently valued at $248.30M, closed the last trade at $2.34 per share which meant it lost -$0.19 on the day or -7.51% during that session. The ADVM stock price is -532.05% off its 52-week high price of $14.79 and 11.54% above the 52-week low of $2.07. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.98 million shares traded. The 3-month trading volume is 2.02 million shares.
The consensus among analysts is that Adverum Biotechnologies Inc. (ADVM) is a Hold stock at the moment, with a recommendation rating of 2.90. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 7 out of 8 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.39.
Adverum Biotechnologies Inc. (NASDAQ:ADVM) trade information
Sporting -7.51% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the ADVM stock price touched $2.34 or saw a rise of 8.95%. Year-to-date, Adverum Biotechnologies Inc. shares have moved -78.41%, while the 5-day performance has seen it change -2.50%. Over the past 30 days, the shares of Adverum Biotechnologies Inc. (NASDAQ:ADVM) have changed -2.90%. Short interest in the company has seen 12.4 million shares shorted with days to cover at 5.29.
Wall Street analysts have a consensus price target for the stock at $3.57, which means that the shares’ value could jump 34.45% from current levels. The projected low price target is $2.00 while the price target rests at a high of $6.00. In that case, then, we find that the current price level is -156.41% off the targeted high while a plunge would see the stock lose 14.53% from current levels.
Adverum Biotechnologies Inc. (ADVM) estimates and forecasts
Figures show that Adverum Biotechnologies Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -77.82% over the past 6 months, with this year growth rate of -11.59%, compared to 7.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -8.30% and -22.60% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 5.80% over the past 5 years.
Adverum Biotechnologies Inc. is expected to release its next earnings report between November 03 and November 08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adverum Biotechnologies Inc. (NASDAQ:ADVM)’s Major holders
Insiders own 2.00% of the company shares, while shares held by institutions stand at 81.82% with a share float percentage of 83.49%. Investors are also buoyed by the number of investors in a company, with Adverum Biotechnologies Inc. having a total of 188 institutions that hold shares in the company. The top two institutional holders are State Street Corporation with over 9.57 million shares worth more than $33.51 million. As of Jun 29, 2021, State Street Corporation held 9.76% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 7.98 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $27.94 million and represent 8.14% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Jun 29, 2021, the former fund manager holds about 8.04% shares in the company for having 7.89 million shares of worth $27.62 million while later fund manager owns 2.5 million shares of worth $24.65 million as of Mar 30, 2021, which makes it owner of about 2.55% of company’s outstanding stock.